Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients
Status:
Completed
Trial end date:
2016-05-11
Target enrollment:
Participant gender:
Summary
This study is a two-part trial consisting of Part A (presented in this record) and Part B
(see NCT02047734).
The primary objective in Part A of this study was to demonstrate the superior efficacy of
ozanimod compared to placebo by showing a reduction in the cumulative number of total
gadolinium-enhancing (GdE) lesions from Week 12 to Week 24 in patients with relapsing
multiple sclerosis (RMS).